This article was originally published in The Gray Sheet
Executive SummarySeries C financing round raises $8.3 mil. The privately-held, Palo Alto, California firm is preparing for clinical trials of its minimally invasive IntraBronchial Volume Reduction system for lung volume reduction treatment of chronic emphysema. The device is intended to eliminate the need for chest incision since it is introduced orally into the patient's airway. Tyco Ventures was the lead venture fund participating in the offering
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.